Sign in

James Creedy

Research Analyst at Goldman Sachs Group Inc.

James Creedy is an analyst at Goldman Sachs Group Inc., specializing in equity research with a primary focus on European banks and financial institutions. He has covered leading companies such as Barclays, HSBC, UBS, and Credit Suisse, establishing a reputation for grounded sector insights and timely investment recommendations. With a background in financial analysis that began in the early 2010s and experience at both boutique research firms and larger investment banks prior to joining Goldman Sachs, Creedy has consistently delivered robust returns and actionable calls, achieving success rates above sector benchmarks and recognition within industry rankings. He holds FINRA Series 7 and 63 licenses and is known for integrating macroeconomic risk analysis into company-level coverage to drive outperformance.

James Creedy's questions to NOVO NORDISK A S (NVO) leadership

Question · Q1 2024

James Creedy asked about the clinical view on desirable fat-to-muscle loss ratios during weight loss and whether data from the SELECT trial indicated any changes in lean body mass composition over time.

Answer

Martin Lange, Head of R&D, explained that physicians generally consider the observed lean mass loss (35-40%) to be within a normal and healthy range for significant weight loss. He cited the positive all-cause mortality data from SELECT as evidence of a healthy weight loss profile and stated he had no specific body composition data from the trial to share.

Ask follow-up questions

Fintool

Fintool can predict NOVO NORDISK A S logo NVO's earnings beat/miss a week before the call

Let Fintool AI Agent track James Creedy for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free